Amicus Therapeutics is an international, public American-based biotechnology company that deals with treatments’ for rare and orphan diseases such as genetic corrective skin disorder, Epidermolysis Bullosa (EB), The Pompe Disease and the Lysosomal Storage Disorder Fabry Disease. It is headquartered in Cranbury, New Jersey and has developed several centers such as the commercial organization, inventive science and clinical programs that ensure the needs of all patients are met. The company has over 500 employees. In 2008, it expanded its research center through opening a second research center in San Diego.
The company was publicly launched in 2007 under the trading symbol FOLD of the NASDAQ. In 2010, the Alzheimer’s Drug Discovery Foundation gave Amicus Therapeutics a $210,300 grant for support of pre-clinical work in collaboration with Icahn School of Medicine at Mount Sinai through the Alzheimer’s disease research center. Later, in November 2013, Amicus Therapeutics obtained their competitor company Callidus Biopharma. This helped it to get the appropriate materials and academic properties to treat the Pompe Disease through the Enzyme Replacement Therapy. This is a disease that damages the nerve cells and muscles throughout the body caused by accumulated glycogens in the lysosome.
In 2015, the company acquired Scioderm, a company that was developing a treatment for Epidermolysis Bullosa (EB), which was known as Zorbalisa or SD-101 (https://seekingalpha.com/article/4073303-amicus-therapeutics-small-biotech-seems-big-mo). This disease is characterized by reoccurring blisters on the skin and fragileness of the skin where the slightest friction or trauma tears it. This treatment was meant to trigger the closure of the wounds and reduce the area coverage of the blisters on the surface of the body.
The company had a three-year collaboration, from 2010 to 2013, with JCR Pharmaceutical and GlaxoSmithKline to conduct research on packaging multiple drugs in one pill with recombinant DNA. This was done with the aim of clinically bringing together genetic materials from different DNA (ReleaseFact). The Michael J. Fox Foundation also gave Amicus Therapeutics a 500,000 dollar grant to support the research done in partnership with the David Geffen School of Medicine at UCLA.